Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Jones RDO"'
Autor:
Vasalou C; Clinical Pharmacology & Safety Sciences, Waltham, Massachusetts, USA., Proia TA; Translational Medicine, Waltham, Massachusetts, USA., Kazlauskas L; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Przybyla A; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Sung M; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Mamidi S; AstraZeneca Research & Development, Cambridge, UK., Maratea K; Clinical Pharmacology & Safety Sciences, Waltham, Massachusetts, USA., Griffin M; Clinical Pharmacology & Safety Sciences, Waltham, Massachusetts, USA., Sargeant R; Clinical Pharmacology & Safety Sciences, Cambridge, UK., Urosevic J; AstraZeneca Research & Development, Cambridge, UK., Rosenbaum AI; Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, South San Francisco, California, USA., Yuan J; Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, South San Francisco, California, USA., Aluri KC; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Ramsden D; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Hariparsad N; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Jones RDO; AstraZeneca Research & Development, Cambridge, UK., Mettetal JT; AstraZeneca Research & Development, Waltham, Massachusetts, USA.
Publikováno v:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Jun; Vol. 13 (6), pp. 994-1005. Date of Electronic Publication: 2024 Mar 26.
Autor:
White MJ; AstraZeneca Research and Development Boston: AstraZeneca R&D Boston, Waltham, Massachusetts, USA. michael.white1@astrazeneca.com., Cheatham L; AstraZeneca Research and Development Boston: AstraZeneca R&D Boston, Waltham, Massachusetts, USA., Wen S; AstraZeneca Research and Development Boston: AstraZeneca R&D Boston, Waltham, Massachusetts, USA., Scarfe G; AstraZeneca Research and Development Boston: AstraZeneca R&D Boston, Waltham, Massachusetts, USA., Cidado J; AstraZeneca Research and Development Boston: AstraZeneca R&D Boston, Waltham, Massachusetts, USA., Reimer C; AstraZeneca Research and Development Boston: AstraZeneca R&D Boston, Waltham, Massachusetts, USA., Hariparsad N; AstraZeneca Research and Development Boston: AstraZeneca R&D Boston, Waltham, Massachusetts, USA., Jones RDO; AstraZeneca Research and Development Boston: AstraZeneca R&D Boston, Waltham, Massachusetts, USA., Drew L; AstraZeneca Research and Development Boston: AstraZeneca R&D Boston, Waltham, Massachusetts, USA., McGinnity DF; AstraZeneca Research and Development Boston: AstraZeneca R&D Boston, Waltham, Massachusetts, USA., Vasalou C; AstraZeneca Research and Development Boston: AstraZeneca R&D Boston, Waltham, Massachusetts, USA.
Publikováno v:
The AAPS journal [AAPS J] 2023 Jun 28; Vol. 25 (4), pp. 66. Date of Electronic Publication: 2023 Jun 28.
Autor:
Vasalou C; Oncology R&D, AstraZeneca, Boston, Massachusetts, United States of America., Harding J; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Jones RDO; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Hariparsad N; Oncology R&D, AstraZeneca, Boston, Massachusetts, United States of America., McGinnity DF; Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
Publikováno v:
PloS one [PLoS One] 2023 May 17; Vol. 18 (5), pp. e0285798. Date of Electronic Publication: 2023 May 17 (Print Publication: 2023).
Autor:
Jones RDO; Oncology R&D, Research and Early Development, AstraZeneca, Cambridge, United Kingdom., Petersson K; qPharmetra LLC, Stockholm, Sweden., Tabatabai A; Oncology R&D, Research & Early Development, AstraZeneca, Waltham, Massachusetts., Bao L; Oncology R&D, Research & Early Development, AstraZeneca, Waltham, Massachusetts., Tomkinson H; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Schuller AG; Oncology R&D, Research & Early Development, AstraZeneca, Waltham, Massachusetts.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2023 May 04; Vol. 22 (5), pp. 679-690.
Autor:
Vasalou C; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Ferguson D; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Li W; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, U.K., Muse V; Novo Nordisk Foundation Center for Protein Research, Copenhagen 2200, Denmark., Gibbons FD; Biogen, Cambridge, Massachusetts 02142, United States., Sonzini S; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, U.K., Zhang G; Dicerna Pharmaceuticals, Inc, Lexington, Massachusetts 02421, United States., Pop-Damkov P; Takeda Pharmaceuticals, Cambridge, Massachusetts 02139, United States., Gangl E; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Balachander SB; Bristol-Myers Squibb, Cambridge, Massachusetts 02142, United States., Wen S; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Schuller AG; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States., Puri S; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, U.K., Mazza M; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, U.K., Ashford M; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, U.K., Fretland AJ; Repare Therapeutics, Cambridge, Massachusetts 02142, United States., McGinnity DF; Oncology R&D, AstraZeneca, Cambridge CB4 0FZ, U.K., Jones RDO; Oncology R&D, AstraZeneca, Cambridge CB4 0FZ, U.K.
Publikováno v:
Molecular pharmaceutics [Mol Pharm] 2022 Jan 03; Vol. 19 (1), pp. 172-187. Date of Electronic Publication: 2021 Dec 10.
Autor:
Jones RDO; Oncology R&D, Research and Early Development, AstraZeneca, Cambridge, UK., Grondine M; Oncology R&D, Research and Early Development, AstraZeneca, Boston, Massachusetts, USA., Borodovsky A; Formerly Oncology R&D, Research and Early Development, AstraZeneca, Boston, Massachusetts, USA., San Martin M; Oncology R&D, Research and Early Development, AstraZeneca, Boston, Massachusetts, USA., DuPont M; Oncology R&D, Research and Early Development, AstraZeneca, Boston, Massachusetts, USA., D'Cruz C; Oncology R&D, Research and Early Development, AstraZeneca, Boston, Massachusetts, USA., Schuller A; Oncology R&D, Research and Early Development, AstraZeneca, Boston, Massachusetts, USA., Henry R; Formerly Oncology R&D, Research and Early Development, AstraZeneca, Boston, Massachusetts, USA., Barry E; Formerly Oncology R&D, Research and Early Development, AstraZeneca, Boston, Massachusetts, USA., Castriotta L; Oncology R&D, Research and Early Development, AstraZeneca, Boston, Massachusetts, USA., Anjum R; Oncology R&D, Research and Early Development, AstraZeneca, Boston, Massachusetts, USA., Petersson K; qPharmetra LLC, Stockholm, Sweden., Sahota T; BioPharmaceuticals R&D, Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge, UK., Ahmed GF; Formerly BioPharmaceuticals R&D, Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge, UK.
Publikováno v:
British journal of pharmacology [Br J Pharmacol] 2021 Feb; Vol. 178 (3), pp. 600-613. Date of Electronic Publication: 2020 Dec 07.
Autor:
Pilla Reddy V; Research and Early Development, Oncology R&D, AstraZeneca, United Kingdom., Anjum R; Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts., Grondine M; Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts., Smith A; Research and Early Development, Oncology R&D, AstraZeneca, United Kingdom., Bhavsar D; Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts., Barry E; Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts., Guichard SM; Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts., Shao W; Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts., Kettle JG; Research and Early Development, Oncology R&D, AstraZeneca, United Kingdom., Brown C; Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts., Banks E; Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts., Jones RDO; Research and Early Development, Oncology R&D, AstraZeneca, United Kingdom. owen.jones@astrazeneca.com.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Jul 15; Vol. 26 (14), pp. 3751-3759. Date of Electronic Publication: 2020 Mar 27.
Autor:
Davies M; DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK. Electronic address: michael.davies@astrazeneca.com., Jones RDO; DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Grime K; DMPK, Research and Early Development, Respiratory, Inflammation and Autoimmune, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Jansson-Löfmark R; DMPK, Research and Early Development, Cardiovascular, Renal and Metabolic, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Fretland AJ; DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Boston, MA, USA., Winiwarter S; DMPK, Research and Early Development, Cardiovascular, Renal and Metabolic, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Morgan P; Mechanistic Safety and ADME Sciences, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK., McGinnity DF; DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
Publikováno v:
Trends in pharmacological sciences [Trends Pharmacol Sci] 2020 Jun; Vol. 41 (6), pp. 390-408. Date of Electronic Publication: 2020 Apr 28.
Autor:
Williamson B; Drug Metabolism and Pharmacokinetics, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Colclough N; Drug Metabolism and Pharmacokinetics, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Fretland AJ; Drug Metabolism and Pharmacokinetics, Research and Early Development, Oncology R&D, AstraZeneca, Boston MA, United States., Jones BC; Drug Metabolism and Pharmacokinetics, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Jones RDO; Drug Metabolism and Pharmacokinetics, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., McGinnity DF; Drug Metabolism and Pharmacokinetics, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
Publikováno v:
Current drug metabolism [Curr Drug Metab] 2020; Vol. 21 (2), pp. 145-162.
Autor:
Bradshaw EL; Takeda, San Diego, California, USA., Spilker ME; Pfizer Worldwide Research and Development, San Diego, California, USA., Zang R; Genentech Inc., South San Francisco, California, USA., Bansal L; GlaxoSmithKline, King of Prussia, Philadelphia, USA., He H; Novartis Institutes for Biomedical Research, East Hanover, New Jersey, USA., Jones RDO; AstraZeneca, Cambridge, UK., Le K; Agios, Cambridge, Massachusetts, USA., Penney M; UCB, Celltech, Slough, Berkshire, UK., Schuck E; Eisai Inc, Woodcliff Lake, New Jersey, USA., Topp B; Merck & Co., Inc, Kenilworth, New Jersey, USA., Tsai A; Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA., Xu C; Sanofi, Bridgewater, New Jersey, USA., Nijsen MJMA; Abbvie Inc, North Chicago, Illinois, USA., Chan JR; Eli Lilly and Company, Indianapolis, Indiana, USA.
Publikováno v:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2019 Nov; Vol. 8 (11), pp. 777-791. Date of Electronic Publication: 2019 Oct 25.